Search Within

Weinberg Fellows

  1. "Ariela Noy"
Formats
  1. Meeting Abstract (50)
  2. Journal Article (20)
  3. Research Letter (4)
  4. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (75)
  2. Department of Medicine (75)
  3. Hematologic Malignancies, Division of (75)
  4. Hematology-Oncology Fellows (75)
  5. Lymphoma (75)
  6. Population Sciences Research Program (60)

More Groups

People
  1. Ariela Noy (75)
  2. Andrew Zelenetz (65)
  3. Maria Palomba (61)
  4. Colette Owens (60)
  5. Anita Kumar (59)
  6. Steven Horwitz (59)

More People

Years
  1. 2025 (5)
  2. 2024 (16)
  3. 2023 (12)
  4. 2022 (7)
  5. 2021 (15)
  6. 2020 (10)

More Years

Publications
  1. Blood (45)
  2. Blood Cancer Journal (5)
  3. Hematological Oncology (5)
  4. Blood Advances (4)
  5. Journal of Clinical Oncology (4)
  6. Haematologica (3)

More Publications

Publishers
  1. American Society of Hematology (49)
  2. Nature Publishing Group (5)
  3. Wiley Blackwell (5)
  4. American Society of Clinical Oncology (4)
  5. Ferrata Storti Foundation (3)
  6. Taylor & Francis Group (3)

More Publishers

Results (75)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
    Correspondence

    Cassanello, G.; Drill, E.; Qiu, A.; Ewalt, M. D.; Hamlin, P.; Horwitz, S. M.; Joffe, E.; Kumar, A.; Moskowitz, A. J.; Noy, A.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: Insights from a retrospective analysis
    Journal Article

    Luttwak, E.; Robin, E. T.; Drill, E.; Boardman, A.; Caron, P.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma
    Research Letter

    Uppal, M.; Joseph, A.; Drill, E.; Hamlin, P.; Falchi, L.; Noy, A.; Owens, C.; Epstein-Peterson, Z. D.; Salles, G.; Zelenetz, A. D.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience
    Journal Article

    Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
    Journal Article

    Ghione, P.; Bantilan, K. S.; Joffe, E.; Palomba, M. L.; Noy, A.; Caron, P.; Hamlin, P.; Kumar, A.; Matasar, M.; Owens, C.; more...
    Blood Neoplasia (2024)

    Fulltext@MSK | Save
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma
    Meeting Abstract

    Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save